Janus kinase inhibitors: jackpot or potluck?
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors. In one of the great victories of translational research in recent times, the first smallmolecule Janus kinase...
Main Authors: | Pavithran Keechilat, Shripad Brahmanand Pande |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2012-06-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/187 |
Similar Items
-
New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
by: Domenico Penna
Published: (2021-10-01) -
Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
by: Hans Hasselbalch, et al.
Published: (2022-11-01) -
Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
by: Hisashi Ishida, et al.
Published: (2020-07-01) -
Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients
by: Cigdem Yuce Kahraman, et al.
Published: (2022-01-01) -
Clinical and laboratory presentations of Janus Kinase II-positive patients in Saudi population
by: H Malhan, et al.
Published: (2014-01-01)